Baker Bros. Advisors LP Macrogenics Inc Transaction History

Baker Bros. Advisors LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$2.25 - $9.99 $1.01 Million - $4.5 Million	450,000 Added 101.68%	892,579 $2.63 Million
Q3 2021 Nov 15, 2021	BUY	$19.74 - $28.7 $4.78 Million - $6.94 Million	241,900 Added 120.54%	442,579 $9.27 Million
Q4 2020 Feb 16, 2021	BUY	$19.41 - $26.0 $3.9 Million - $5.22 Million	200,679 New	200,679 $4.59 Million
Q2 2019 Aug 14, 2019	SELL	$14.51 - $19.71 $4.39 Million - $5.96 Million	-302,600 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$11.11 - $25.6 $3.36 Million - $7.75 Million	302,600 New	302,600 $5.44 Million
Q3 2018 Nov 14, 2018	SELL	$19.26 - $23.46 $4.19 Million - $5.11 Million	-217,695 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$19.78 - $24.67 $2.89 Million - $3.6 Million	-145,981 Reduced 40.14%	217,695 $4.5 Million
Q3 2017 Nov 14, 2017	BUY	$15.52 - $18.94 $5.64 Million - $6.89 Million	363,676	363,676 $6.72 Million

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Baker Bros. Advisors LP with notifications on news.